Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.
An opinionated take on NEJM highlights for the fourth quarter of 2024
By
Marc Herant
NEJM
Preempting severe genetic disease
Around 2% of births come with a gene…
Read more
An opinionated take on NEJM highlights for the third quarter of 2024
By
Marc Herant
NEJM
The new Humira?
It’s not that often that you see industry-sponsored h…
Read more
An opinionated take on NEJM highlights for the fourth quarter of 2023
By
Marc Herant
NEJM
A Chinese study uncovers a new use for an old drug
Bleeding in the sma…
Read more
An opinionated take on NEJM highlights for the third quarter of 2023
By
Marc Herant
NEJM
How the US taxpayer saved 25M+ people
A short piece celebrating the 20…
Read more
An opinionated take on NEJM highlights for the first quarter of 2023
By
Marc Herant
NEJM
Hypertension?!
Antihypertensive drugs are so 80s and 90s (well, except…
Read more
Hearts and souls: An opinionated take on NEJM highlights for October and November 2022
By
Marc Herant
NEJM
A psychedelic for refractory depression
While major depression is awfu…
Read more
An innovative sales strategy for a pivotal drug; Novartis trailblazes with Leqvio
By
Thomas Uhler and Jason Brauner
Biopharma
After the $9.7B acquisition of The Medicines Company two and a half ye…
Read more
An opinionated take on NEJM highlights for January-February 2021
By
Marc Herant
NEJM
Gene therapy in beta-thalassemia and sickle cell anemia
Beta-thalassem…
Read more
While we wait for our shot(s); an opinionated take on NEJM highlights for January 2021
By
Marc Herant
NEJM
Incremental progress in the fight to treat heart failure
After a decad…
Read more
Closing a tough year: An opinionated take on NEJM highlights for December 2020
By
Marc Herant
NEJM
Cardiovascular health – go big or go narrow?
A follow up on the devel…
Read more
We are back and catching-up: An opinionated take on NEJM highlights for Sep, Oct, and Nov 2020
By
Marc Herant
NEJM
Small but real progress in ALS:
Despite enormous public attention and …
Read more
Tax dollars doing good work: An opinionated take on NEJM highlights for December 2019
By
Marc Herant
NEJM
The loneliness of the patent-less drug
Colchicine is a very old drug c…
Read more
An opinionated take on NEJM highlights for May 2019
By
Marc Herant
NEJM
TAVR for all?
TAVR has become the standard of care for patients who ne…
Read more
An opinionated take on NEJM highlights for March 2019
By
Marc Herant
NEJM
Target assessment with genetic polymorphisms
Please bear with me for a…
Read more
Eating your way out of disease: An opinionated take on NEJM highlights for November 2018
By
Marc Herant
NEJM
Peanut medicine that won’t cost peanuts
Allergy to peanuts is a major …
Read more
An opinionated take on NEJM highlights for September 2018
By
Marc Herant
NEJM
Primary care organizations are better ACOs when it comes to achieving …
Read more
An opinionated take on NEJM highlights for April 2018
By
Marc Herant
NEJM
Are we nearing an asymptote with implantable cardiac pumps?
Severe hea…
Read more
An opinionated take on NEJM highlights for February 2018
By
Marc Herant
NEJM
A-fib in heart failure – time to be aggressive
Over the last 15 years,…
Read more
Between the very common and the very rare – An opinionated take on NEJM highlights for October 2017
By
Marc Herant
NEJM
Between the very common and the very rare – An opinionated take on NEJ…
Read more
An opinionated take on NEJM highlights for July 2017
By
Marc Herant
NEJM
Taking stock: two decades of progress in heart failure:
Here comes a c…
Read more
An opinionated take on NEJM highlights for May 2017
By
Marc Herant
NEJM
A hammer finds new nails (which happen to be eyeballs)
The insulin gro…
Read more
April was a light month: an opinionated take on NEJM highlights for April 2017
By
Marc Herant
NEJM
Calendaring care
The length of our sidereal year is an accident – we h…
Read more
A population health approach to value-based drug pricing
By
Marc Herant
Biopharma
,
Payers
Working Paper
Summary
Drug companies are naturally incentivized…
Read more
Regeneration and mitigation: an opinionated take on NEJM highlights for March 2017
By
Marc Herant
NEJM
Gene therapy for sickle cell disease
Typical diseases targeted by gene…
Read more
NEJM Highlights for May 2016: Referral for surgery, and a miscellany of interesting biochemistry
By
Marc Herant
NEJM
Surgical volume and referral for surgery:
The impact of surgical volum…
Read more
NEJM Highlights November 2015: systems biology, RSV progress, a first in diabetes, hypertension goals, the case of Maryland
By
Marc Herant
NEJM
Systems biology finally gets real: an unexpected use for a diabetes dr…
Read more
NEJM Highlights for June 2015: the flavor of the month is distinctly cardiovascular
By
Marc Herant
NEJM
Interventionalist treatment for stroke:
In the 80s and 90s, treatment …
Read more
NEJM Highlights April 2015
By
Marc Herant
NEJM
The rise, fall, and rebirth of the Chinese healthcare system
A fascina…
Read more
NEJM Highlights March 2015: Progress against Crohn’s, PCSK9 inhibitors coming through, comparative effectiveness for diabetic macular edema, Eric Lander encourages the FDA on genomic testing regulation
By
Marc Herant
NEJM
A promising agent for Crohn’s Disease, a miserable illness
Crohn’s is …
